Pulmonary Eosinophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Large reductions in exacerbation rates were observed compared to placebo, though only benralizumab was sufficiently powered (n = 2051) to demonstrate significantly decreased exacerbation rates in the subgroup analysis of IL-5 acting agents compared to placebo.Monoclonal antibodies such as mepolizumab, reslizumab and benralizumab have proven their benefit to reduce exacerbation rates in severe persistent eosinophilic asthma in the published trials.
|
31395084 |
2019 |
Pulmonary Eosinophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-3-upregulated genes may provide a foundation for research into therapeutics for patients with eosinophilic asthma who do not respond to anti-IL-5 therapies.
|
31175163 |
2019 |
Pulmonary Eosinophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several monoclonal antibody therapies targeting interleukin (IL)-4/IL-13 and IL-5 cytokine pathways have been developed for the treatment of severe eosinophilic asthma.
|
30407206 |
2019 |
Pulmonary Eosinophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Areas covered</b>: In this review, we discuss the role and pathogenesis of IL-5 and eosinophils in asthma and rationale of antagonizing IL-5 in severe eosinophilic asthma.
|
31009582 |
2019 |
Pulmonary Eosinophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that purified human eosinophils stimulated with IL-5 predominantly secreted CCL4 and that patients with EP had elevated CCL11 and CCL4 levels in BALF compared with samples from individuals without EP.
|
30854716 |
2019 |
Pulmonary Eosinophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several major randomized control studies have demonstrated that mepolizumab, an anti-IL-5 monoclonal antibody, is effective for patients with severe eosinophilic asthma who show exacerbation or require systemic corticosteroid maintenance therapy.
|
31606052 |
2019 |
Pulmonary Eosinophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mepolizumab is an anti-IL-5 antibody approved for the treatment of severe eosinophilic asthma.
|
31201938 |
2019 |
Pulmonary Eosinophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Benralizumab, a humanized, anti-interleukin-5 (anti-IL-5) receptor α monoclonal antibody that directly and rapidly depletes eosinophils, has shown significant efficacy in reducing asthma exacerbations and improving lung function in moderate to severe eosinophilic asthma patients.
|
31145343 |
2019 |
Pulmonary Eosinophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> The interleukin 5 (IL-5) pathway is an important component in the pathophysiology of severe eosinophilic asthma.
|
31479312 |
2019 |
Pulmonary Eosinophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mepolizumab, a humanized monoclonal antibody that neutralizes IL-5 and efficiently attenuates eosinophils, proved clinically effective in severe eosinophilic asthma but not in mild asthma.
|
30192638 |
2019 |
Pulmonary Eosinophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Eosinophilic asthma is often due to a type-2 immune response and production of IL-5, which leads to eosinophilopiesis and recruitment of mature eosinophils in the airways.
|
30906226 |
2019 |
Pulmonary Eosinophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Instead, mepolizumab (blocking the IL5 ligand) should be considered for 'eosinophilic' asthma.
|
31414917 |
2019 |
Pulmonary Eosinophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-IL-5/IL-5R biologics are indicated in patients with severe eosinophilic asthma and repetitive exacerbations, irrespective of the presence or absence of allergy.
|
30961951 |
2019 |
Pulmonary Eosinophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Biologics targeting IL-5 and its receptor (first mepolizumab and subsequently, reslizumab and benralizumab), have been recently approved and used as add-on therapy for severe eosinophilic asthma resulting in a reduction in the circulating eosinophil count, improvement in lung function and exacerbation reduction in asthma patients.
|
30354852 |
2019 |
Pulmonary Eosinophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review focuses on benralizumab as an alternative to other agents targeting the IL-5 pathway in the treatment of eosinophilic asthma.
|
31017107 |
2019 |
Pulmonary Eosinophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
There are still a number of unresolved issues related to the anti-IL5 strategy in eosinophilic asthma, which are here reviewed.
|
30498762 |
2018 |
Pulmonary Eosinophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This short review discusses recent studies of the effectiveness of the anti-IL-5 reslizumab in relation to the use of simple reproducible biomarkers in eosinophilic asthma.
|
29554826 |
2018 |
Pulmonary Eosinophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In placebo-controlled trials, reslizumab, an anti-IL-5 monoclonal antibody, significantly reduced asthma exacerbations and improved lung function and asthma control in patients with eosinophilic asthma.
|
29122156 |
2018 |
Pulmonary Eosinophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since IL-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting IL-5/IL-5Rα have been developed and/or marketed, including Mepolizumab, Reslizumab, and Benralizumab.
|
29059618 |
2018 |
Pulmonary Eosinophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also review the evidence to date regarding the efficacy of mepolizumab (an anti-IL-5 monoclonal antibody) in severe eosinophilic asthma and the smaller evidence base regarding its efficacy in EGPA, an indication for which it recently received U.S. Food and Drug Administration approval.
|
29637936 |
2018 |
Pulmonary Eosinophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mepolizumab is a humanized monoclonal antibody which targets interleukin-5 (IL-5) and is nowadays available in many countries for add-on biological therapy of severe eosinophilic asthma.
|
30217438 |
2018 |
Pulmonary Eosinophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
One notable exception is the targeting of eosinophilic airway inflammation with anti-IL-5, which has an acknowledged and important role in the treatment of severe eosinophilic asthma.
|
29729941 |
2018 |
Pulmonary Eosinophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response.
|
30021546 |
2018 |
Pulmonary Eosinophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Within such a context, the anti-IL-5 monoclonal antibodies mepolizumab and reslizumab have been developed and approved for biological therapy of uncontrolled eosinophilic asthma.
|
29862274 |
2018 |
Pulmonary Eosinophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, for uncontrolled patients with severe eosinophilic asthma, who are not fully responsive to corticosteroids, IL-5 represents a very important molecular target for add-on biological therapies.
|
29606855 |
2018 |